Additional studies have expanded the clinical application of ADAMTS13 testing beyond thrombotic microangiopathies into liver diseases, as reduced ADAMTS13 levels directly correlate with the progression and severity of liver cirrhosis. This evidence concerns the gene ADAMTS13 and Genetic thrombotic microangiopathy.